Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

BBV152

Vaccine (Inactivated vaccine) · Immune activation, directed at SARS-CoV-2 spike protein · developed by Bharat Biotech International

Phase 2/3 Most advanced trial (none active)
1 Registered trials

What is BBV152?

BBV152 (Covaxin) is an inactivated whole-virion SARS-CoV-2 vaccine. Upon administration, it induces neutralizing antibodies against SARS-CoV-2, providing active immunization against COVID-19.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Covaxin
Drug type
Vaccine (Inactivated vaccine)
Targets
SARS-CoV-2 spike protein (antigen)
Mechanism
Immune activation, directed at SARS-CoV-2 spike protein
Pathways
immune_activation
Therapy area
Infectious disease
Developer
Bharat Biotech International Limited
In trials of
OCGN
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII
76JZE5DSN6

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05258669 Phase 2/3 COVID-19 Unknown OCGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

COVID-19

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.